DW532
DW532 is a dual inhibitor of tubulin and tyrosine kinase, with IC50 values of 4.9 μM and 5.5 μM against EGFR and VEGFR2, respectively, and a KD of 3.6 μM for tubulin. DW532 induces cell cycle arrest at the G2/M phase, triggers cell apoptosis via caspase-related pathways, and inhibits angiogenesis. DW532 can be used for research related to cancers (e.g., breast cancer).
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1267949-42-7
- Fòrmula: C16H12O6
- Peso molecular:300.27
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas EGFR
MoreVer todos los productos específicos de isoformas VEGFR
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
VEGFR2 5.5 μM (IC50) |
EGFR 4.9 μM (IC50) |
C-src 8.6 μM (IC50) |
In Vitro
DW532 (1-10 μM; 2 h) dose-dependently inhibits ligand-induced VEGFR2 activation and its downstream signaling pathways in HUVECs, as well as EGFR activation and its downstream signaling pathways in A431 human epithelial cancer cells[1].
DW532 (10-40 μM; 30 min) is a microtubule destabilizer that inhibits tubulin polymerization in vitro in a dose-dependent manner[1].
DW532 (0.1-10 μM; 12 h) dose-dependently inhibits tubulin polymerization in human breast cancer MDA-MB-468 cells, reduces the level of polymerized tubulin and increases the level of soluble tubulin[1].
DW532 (10 μM; 6 h) disrupts the microtubule network in human lung cancer A549 cells and induces diffuse tubulin staining, which is consistent with the characteristics of microtubule destabilization[1].
DW532 (72 h) potently and non-selectively inhibits the proliferation of a panel of 16 human cancer cell lines, with a mean IC50 of 1.82 μM[1].
DW532 (0.1-10 μM; 6 h) dose-dependently inhibits tube formation in human umbilical vein endothelial cells (HUVECs) in vitro[1].
DW532 (10 μM; 12 h) disrupts mitotic spindle assembly in human lung cancer A549 cells, induces chromosome dispersion and multipolar spindle formation, and rarely causes the appearance of monopolar spindles[1].
DW532 (1-10 μM; 24 h) induces G2/M phase arrest in MDA-MB-468, A549, PC-3, KB, K562 and A431 human cancer cells, accompanied by altered levels of mitosis-related proteins cyclin B1, p-CDK1 and p-H3[1].
DW532 (0.1-20 μM; 48 h) induces dose-dependent apoptosis in KB, MDA-MB-468 and A431 human cancer cells via a caspase-related mechanism[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human umbilical vein endothelial cells (HUVECs), A431 human epithelial cancer cells
-
Concentration:1, 5 and 10 μM
-
Incubation Time:2 h (pre-incubated prior to 15 min ligand stimulation)
-
Result:Dose-dependently inhibited VEGF-induced phosphorylation of VEGFR2 and its downstream target Akt in HUVECs.
Similarly inhibited EGF-induced phosphorylation of EGFR and downstream Akt in A431 cells.
-
Cell Line:MDA-MB-468 human breast carcinoma cells
-
Concentration:0.1, 1 and 10 μM
-
Incubation Time:12 h
-
Result:Dose-dependently decreased polymerized tubulin in pellets and increased soluble tubulin in supernatants, promoting the transition of cellular tubulin from polymerized to free state.
-
Cell Line:A549 human lung cancer cells
-
Concentration:10 μM
-
Incubation Time:6 h
-
Result:Disrupted the intact, stretched microtubule network seen in untreated cells, resulting in dispersed tubulin staining similar to that induced by the microtubule destabilizer vincristine (VCR).
-
Cell Line:A549 human lung cancer cells
-
Concentration:10 μM
-
Incubation Time:12 h
-
Result:Induced scattered chromosomes in the cytoplasm, formation of multipolar spindles, and a small proportion of monopolar spindles, consistent with traditional microtubule destabilizers.
-
Cell Line:KB mouth epidermal carcinoma cells, MDA-MB-468 human breast carcinoma cells, A431 human epithelial carcinoma cells
-
Concentration:0.1, 1 and 10 μM (Annexin V/PI); 0.1, 1, 5, 10 and 20 μM (Western Blot)
-
Incubation Time:48 h
-
Result:Induced dose-dependent apoptosis: ~59.7% of KB cells underwent apoptosis at 1 μM, and ~70% at 10 μM.
Dose-dependently increased cleavage of caspase-3, caspase-9, and PARP, indicating a caspase-related apoptosis mechanism.
-
Cell Line:MDA-MB-468, A549, PC-3, KB, K562, and A431 human cancer cells
-
Concentration:1 and 10 μM
-
Incubation Time:24 h
-
Result:Arrested all six tested cell lines at the G2/M phase.
Increased levels of mitotic markers cyclin B1 and p-H3, and decreased levels of phosphorylated (inhibitory) CDK1 (Tyr15).
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:fertilized eggs[1]
-
Dosage:0.1 nmol per egg; 1 nmol per egg
-
Administration:local application
-
Result:Significantly inhibited neovascularization at both tested doses compared to untreated controls.
Chemical Information
-
No. CAS 1267949-42-7
-
Peso molecular 300.27
-
Fòrmula C16H12O6
-
SMILES
O=C1OC=2C(O)=C(O)C=CC2C(=C1)C=3C=CC(OC)=C(O)C3
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)